These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: LncRNA NR2F1-AS1 is involved in the progression of endometrial cancer by sponging miR-363 to target SOX4.
    Author: Wang L, Zhao S, Mingxin YU.
    Journal: Pharmazie; 2019 May 01; 74(5):295-300. PubMed ID: 31109400.
    Abstract:
    This study intended to investigate the role of lncRNA NR2F1-AS1 in endometrial cancer (EC). The expression level of NR2F1-AS1 in tumor tissues and EC cells was measured. After sh-NR2F1-AS1 transfection, the cell viability, apoptosis, migration and invasion of EC cells were analyzed. Luciferase reporter assay was conducted to investigate the target gene of miR-363. The expression levels of PI3K/AKT/GSK-3β pathway-associated factors were assayed using western blot. NR2F1-AS1 was significantly overexpressed in EC tissues and cells. NR2F1-AS1 inhibition decreased EC cell viability, migration and invasion, while promoted cell apoptosis. miR-363 was negatively regulated by NR2F1-AS1. SOX4 was a target of miR-363. NR2F1-AS1 functioned on EC progression via PI3K/AKT/GSK-3β pathway. The results demonstrated that NR2F1-AS1 was highly expressed in EC, which involved in the proliferation and migration of EC cells through downregulation of miR-363 to target SOX4 and regulating PI3K/AKT/GSK-3β pathway.
    [Abstract] [Full Text] [Related] [New Search]